BridgeBio Oncology Therapeutics, Inc. (BBOT) competitors & alternatives
Health Care · NASDAQ
BridgeBio Oncology Therapeutics, Inc. (BBOT)'s top competitors and alternatives — its most similar public companies — include Revolution Medicines (RVMD), ARCUS BIOSCIENCES INC (RCUS), Summit Therapeutics (SMMT), Exelixis (EXEL), ONKURE THERAPEUTICS INC CLASS A (OKUR), IMMUNEERING CORP CLASS A (IMRX), NUVATION BIO INC CLASS A (NUVB), BLACK DIAMOND THERAPEUTICS INC (BDTX), TYRA BIOSCIENCES INC (TYRA), WHITEHAWK THERAPEUTICS INC (WHWK), ARRIVENT BIOPHARMA INC (AVBP) and IOVANCE BIOTHERAPEUTICS INC (IOVA). These are BridgeBio Oncology Therapeutics, Inc.'s closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top BBOT competitors & alternatives
-
Revolution MedicinesRVMDHealth Care
A precision oncology biotech in clinical development stages, pursuing targeted cancer therapies with no approved products yet but backed by substantial capital.
$183.03 (as of 2026-07-22) · market cap $39.0B
-
ARCUS BIOSCIENCES INCRCUSHealth Care
A clinical-stage biotech developing first-in-class and best-in-class small molecules and antibodies for cancer immunotherapy, with lead HIF-2α inhibitor in…
$29.97 (as of 2026-07-22) · market cap $3.7B
-
Summit TherapeuticsSMMTHealth Care
Oncology-focused biotech developing ivonescimab, a first-in-class bispecific antibody combining PD-1 immunotherapy with anti-VEGF anti-angiogenesis, with Phase…
$14.74 (as of 2026-07-22) · market cap $11.4B
-
ExelixisEXELHealth Care
Exelixis is a profitable oncology company commercializing the multi-kinase inhibitor cabozantinib across multiple cancer indications while advancing a pipeline…
$54.98 (as of 2026-07-22) · market cap $14.0B
-
ONKURE THERAPEUTICS INC CLASS AOKURHealth Care
OnKure Therapeutics is a clinical-stage biotech developing precision small molecule drugs that selectively target mutated proteins to treat cancer and vascular…
$4.32 (as of 2026-07-22) · market cap $175M
-
IMMUNEERING CORP CLASS AIMRXHealth Care
Immuneering is a clinical-stage oncology company developing Deep Cyclic Inhibitors, a novel class of MEK/MAPK inhibitors designed to improve durability and…
$4.47 (as of 2026-07-22) · market cap $289M
-
NUVATION BIO INC CLASS ANUVBHealth Care
A recently commercialized, oncology-focused biotech leveraging deep medicinal chemistry expertise to develop targeted small-molecule cancer therapies, with its…
$6.55 (as of 2026-07-22) · market cap $2.2B
-
BLACK DIAMOND THERAPEUTICS INCBDTXHealth Care
Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey inhibitors designed to target families of oncogenic mutations across…
$1.83 (as of 2026-07-22) · market cap $106M
-
TYRA BIOSCIENCES INCTYRAHealth Care
Tyra Biosciences is a clinical-stage biotech company developing precision small-molecule inhibitors to overcome drug resistance in cancer, particularly…
$30.59 (as of 2026-07-22) · market cap $1.8B
-
WHITEHAWK THERAPEUTICS INCWHWKHealth Care
Clinical-stage oncology company developing next-generation antibody-drug conjugates (ADCs) targeting validated tumor antigens with advanced linker-payload…
$3.99 (as of 2026-07-22) · market cap $216M
-
ARRIVENT BIOPHARMA INCAVBPHealth Care
Arrivent Biopharma is a clinical-stage oncology company advancing firmonertinib, an EGFR-targeted tyrosine kinase inhibitor for treating non-small cell lung…
$30.44 (as of 2026-07-22) · market cap $1.3B
-
IOVANCE BIOTHERAPEUTICS INCIOVAHealth Care
Iovance delivers Amtagvi, the first FDA-approved individualized TIL cell therapy for advanced melanoma, with a pipeline expanding to lung cancer and sarcoma…
$5.17 (as of 2026-07-22) · market cap $2.3B
Not quite? Describe exactly what you want →
Peers are BridgeBio Oncology Therapeutics, Inc.'s closest public companies by shared sub-industry, sector and business themes. See the full profile: BridgeBio Oncology Therapeutics, Inc. (BBOT).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.